Insulin sensitivity and premenstrual syndrome

Current Diabetes Reports

Volumn 4, Issue 4, 2004, Pages 273-280

  Trout, Kimberly K ^b   Teff, Karen L ^a  

^a MONELL CHEMICAL SENSES CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CARBONATE; DESOGESTREL; DROSPIRENONE; ESTRANE DERIVATIVE; ESTROGEN; ETHINYLESTRADIOL; FENFLURAMINE; FLUOXETINE; GESTAGEN; GLIBENCLAMIDE; GLUCOSE; GONANE DERIVATIVE; INSULIN; MAGNESIUM OXIDE; MEFENAMIC ACID; MONOAMINE OXIDASE INHIBITOR; NORETHISTERONE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PROSTAGLANDIN INHIBITOR; PYRIDOXINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULFONYLUREA;

ANOREXIA; APPETITE DISORDER; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE EXACERBATION; DIZZINESS; DRUG COST; DRUG MECHANISM; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONE ACTION; HUMAN; INSULIN SENSITIVITY; LETHARGY; MENSTRUAL CYCLE; MOOD DISORDER; NAUSEA; NUTRITIONAL SUPPORT; PATHOGENESIS; PHYSICAL DISEASE; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; REVIEW; SEXUAL DYSFUNCTION; SLEEP DISORDER; SYMPTOMATOLOGY; TREMOR; VITAMIN SUPPLEMENTATION;

EID: 4444254928     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-004-0079-4     Document Type: Review

References (58)

1. Lunt H, Brown LJ: Self-reported changes in capillary glucose and insulin requirements during the menstrual cycle. Diabet Med 1996, 13:525-530.
2. Cawood EH, Bancroft J, Steel JM: Perimenstrual symptoms in women with diabetes mellitus and the relationship to diabetic control. Diabet Med 1993, 10:444-448.
3. Cramer HI: The influence of menstruation on carbohydrate tolerance in diabetes mellitus. CMAJ 1942, 47:51-55.
4. Pulido JME, Salazar MA: Changes in insulin sensitivity, secretion and glucose effectiveness during menstrual cycle. Arch Med Res 1999, 30:19-22.
5. Valdes CT, Elkind-Hirsch KE: Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle. J Clin Endocrinol Metab 1991, 72:642-646.
6. Ezenwaka EC, Akanji AO, Adejuwon CA, et al.: Insulin responses following glucose administration in menstruating women. Int J Gynecol Obstet 1993, 42:155-159.
7. Spellacy WN, Ellingson AB, Keith G, et al.: Plasma glucose and insulin levels during the menstrual cycles of normal women and premenstrual syndrome patients. J Reprod Med 1990, 35:508-511.
8. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214-E223.
9. Bergman RN, Prager R, Volund A, Olefsky JM: Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987, 79:790-800.
10. Widom B, Diamond MP, Simonson DC: Alterations in glucose metabolism during menstrual cycle in women with IDDM. Diabetes Care 1992, 15:213-220.
11. Scott AR, Macdonald IA, Bowman CA, Jeffcoate WJ: Effect of phase of menstrual cycle on insulin sensitivity, peripheral blood flow and cardiovascular responses to hyperinsulinaemia in young women with type 1 diabetes. Diabet Med 1990, 7:57-62.
12. Moberg E, Kollind M, Lins PE, Adamson U: Day-to-day variation of insulin sensitivity in patients with type 1 diabetes: role of gender and menstrual cycle. Diabet Med 1995, 12:224-228.
13. Strotmeyer ES, Steenkiste AR, Foley TP, et al.: Menstrual cycle differences between women with type 1 diabetes and women without diabetes. Diabetes Care 2003, 26:1016-1021.
14. Solomon CG, Hu FB, Dunaif A, et al.: Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 2001, 286:2421-2426.
15. Beckles GLA, Thompson-Reid PE, eds: Diabetes and Women's Health Across the Life Stages: A Public Health Perspective. Atlanta: U.S. Department of Health and Human Services, Center for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation; 2001
16. Rubin RR, Peyrot M: Was Willis right? Thoughts on the interaction of depression and diabetes. Diabetes Metab Res Rev 2002, 18:173-175.
17. Chu PC, Lin MT, Shian RL, Leu SY: Alterations in physiologic functions and in brain monoamine content in streptozocin-diabetic rats. Diabetes 1986, 35:481-485.
18. Steiner M, Pearlstein T: Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry 2000, 61(suppl 12):17-21.
19. American College of Obstetricians and Gynecologists: Premenstrual Syndrome. ACOG Practice Bulletin No. 15. Washington, DC: American College of Obstetricians and Gynecologists; 2000.
20. Ugarizza DN, Klingner S, O'Brien S: Premenstrual syndrome: diagnosis and intervention. Nurse Pract 1998, 23:44-58.
21. Magyar DM, Boyers SP, Marshall JR, Abraham GE: Regular menstrual cycles and premenstrual molimina as indicators of ovulation. Obstet Gynecol 1979, 53:411-414.
22. Budeiri DJ, Po ALW, Dornan JC: Clinical trials of treatments of premenstrual syndrome: entry criteria and scales for measuring treatment outcomes. Br J Obstet Gynaecol 1994, 101:689-695.
23. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4 (text revision). Washington, DC: American Psychiatric Association; 2000.
24. Ling FW: Recognizing and treating premenstrual dysphoric disorder in the obstetric, gynecologic, and primary care practices. J Clin Psychiatry 2000, 61:9-16.
25. Dennerstein L, Brown JB, Gotts G, et al.: Menstrual cycle hormonal profiles of women with and without premenstrual syndrome. J Psychosom Obstet Gynaecol 1993, 14:259-268.
26. Rubinow DR, Hoban MC, Grover GN, et al.: Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol 1988, 158:5- 11.
27. Schmidt PJ, Nieman LK, Danaceau MA, et al.: Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998, 338:209-216.
28. Steiner M, Steinberg S, Stewart D, et al.: Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 1995, 332:1529-1534.
29. Rapkin A: A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003, 28:39-53.
30. Wonsiewicz MJ, Morriss JM, eds: Goodman and Gilman's The Pharmacological Basis of Therapeutics, edn 10. New York: McGraw-Hill; 2001.
31. Halbreich U, Tworek H: Altered serotonergic activity in women with dysphoric premenstrual syndromes. Int J Psychiatry Med 1993, 23:1-27.
32. Jermain DM, Preece CK, Sykes RL, et al.: Luteal phase sertraline treatment for premenstrual dysphoric disorder. Arch Fam Med 1999, 8:328-332.
33. Reith MAE, ed: Neurotransmitter Transporters: Structure, Function, and Regulation. Totowa, NJ: Humana Press; 1997.
34. Biegon A, Bercovitz H, Samuel D: Serotonin receptor concentration during the estrous cycle of the rat. Brain Res 1980, 187:221-225.
35. Guidotti A, Costa E: Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3a, 5a-tetrahydroprogesterone (allopregnanolone) availability? Biol Psychiatry 1998, 44:865-873.
36. Girdler SS, Straneva PA, Light KC, et al.: Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 2001, 49:788-797.
37. Purdy RH, Moore PH, Morrow AL, Paul SM: Neurosteroids and GABA-A receptor function. In GABAergic Synaptic Transmission. Edited by Biggio G, et al. New York: Raven Press; 1992:87-102.
38. Smith SS, Gong QH, Hsu FC, et al.: GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 1998, 392:926-930.
39. Hajduch E, Rencurel E, Balendran A, et al.: Serotonin (5-hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle. J Biol Chem 1999, 274:13563-13568.
40. Endo Y: Evidence that the accumulation of 5-hydroxytryptamine in the liver but not in the brain may cause the hypoglycemia induced by 5-hydroxytryptophan. Br J Pharmacol 1985, 85:591-598.
41. Chaouloff F, Gunn SH, Young JB: Central 5-hydroxytryptamine-2 receptors are involved in the adrenal catecholamine-releasing and hyperglycemic effects of the 5-hydroxytryptamine indirect agonist d-fenfluramine in the conscious rat. J Pharmacol Exp Ther 1992, 260:1008-1016.
42. Potter van Loon BJ, Radder JK, Frolich M, et al.: Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals. Int J Obes 1992, 16:79-85.
43. O'Kane M, Wiles PG, Wales JK: Huoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994, 11:105-110.
44. Pestell RG, Crock PA, Ward GM, et al.: Fenfluramine increases insulin action in patients with NIDDM. Diabetes Care 1989, 12:252-258.
45. Scheen AJ, Paolisso G, Salvatore T, Lefebvre PJ: Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine. Diabetes Care 1991, 14:325-332.
46. Proietto J, Thorburn AW, Fabris S, Harrison LC: Effects of dexfenfluramine on glucose turnover in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1994, 23:127-134.
47. Takhar J, Williamson P: Hypoglycemia associated with high doses of sertraline and sulphonylurea compound in a noninsulin-dependent diabetes mellitus patient. Can J Clin Pharmacol 1999, 6:12-14.
48. Dalvit-McPhillips SP: The effect of the human menstrual cycle on nutrient intake. Physiol Behav 1983, 31:209-212.
49. Wurtman JJ, Brzezinski A, Wurtman RJ, Laferrere B: Effect of nutrient intake on premenstrual depression. Am J Obstet Gynecol 1989, 161:1228-1234.
50. Sayegh R, Schiff I, Wurtman J, et al.: The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. Obstet Gynecol 1995, 86:520-528.
51. Teff KL, Young SN, Blundell JE: The effect of protein or carbohydrate breakfasts on subsequent amino acid levels, satiety and nutrient selection in normal males. Pharmacol Biochem Behav 1989, 4:829-837.
52. Wyatt K Dimmock P, O'Brien PM: Premenstrual syndrome. Clin Evid 2000, 4:1121-1133.
53. Shoupe D: Effects of desogestrel on carbohydrate metabolism. Am J Obstet Gynecol 1993, 168(3 Pt 2):1041-1047.
54. Gaspard U, Scheen A, Endrikat J. et al.: A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception 2003, 67:423-429.
55. Baron AD, Laakso M, Brechtel G, Edelman SV: Mechanism of insulin resistance in insulin-dependent diabetes mellitus: a major role for reduced skeletal muscle blood flow. J Clin Endocrinol Metab 1991, 73:637-643.
56. DeSouza MC, Walker AF, Robinson PA, Bolland K: A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J Womens Health Gend Based Med 2000, 9:131-139.
57. Thys-Jacobs S, Starkey P, Bernstein D, Tian J: Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 1998, 179:444-452.
58. Thys-Jacobs S, Ceccarelli S, Bierman A, et al.: Calcium supplementation in premenstrual syndrome: a randomized crossover trial. J Gen Intern Med 1989, 4:183-189.